www.wjpps.com Vol 3, Issue 2, 2014.
844
Gehad et al. World Journal of Pharmacy and Pharmaceutical Sciences
SPECTROPHOTMETRIC DETERMINATION OF SOME
FLOUROQUINOLONE DRUGS IN TABLETS.
Gehad G. Mohamed1, Shaban M. Khalil2, Samah H. Mahmoud1
1Chemistry Department, Faculty of Science, Cairo University, 12613, Giza, Egypt. 2National Organization for Drug Control and Research, Pyramids street, Giza, Egypt.
ABSTRACT
This work described the use of spectrophotometric methods for the
determination of some antibiotic flouroquinolone drugs namely
sparfloxacin (SFX), levofloxacin (LFX), ofloxacin (OFX) and
enrofloxacin (EFX) in pure form and in tablets. The first method is
based on charge transfer complex formation between these drugs as n-
electron donors and 7,7,8,8-tetracyanoquinodimethane (TCNQ) and
5,6-dicyano-1,4-benzoquinone (DDQ) as π-acceptors. The
experimental conditions for these CT reactions have been carefully
optimized. Beer’s law is valid over the concentration range from 5-150
and 5-180 µg mL-1 of SFX, LFX and OFX and SFX, LFX and EFX
drugs using DDQ and TCNQ reagents, respectively. The second
method is based on ion-pair formation between these drugs and
Mo(V)-thiocyanate reagent in sulphuric acid medium and extraction
with 1,2-dichloro-ethane. Beer’s law is valid over the concentration
range from 10-150, 10-125, 10-90 and 10-90 µg mL-1 for SFX, LFX, OFX and EFX drugs,
respectively. Different analytical parameters namely molar absorptivity (), standard
deviation, relative standard deviation, correlation coefficient, limit of detection and
quantification are calculated. The results obtained by the proposed methods are in good
agreement with those obtained by the official method as indicated by the percent recovery
values. The methods are applied for the determination of these flouroquinolone drugs in
tablets.
Keywords: Floroquinolone drugs; DDQ; TCNQ; Mo(V)-thiocyanate; spectrophotometry;
charge-transfer; ion-pair formation.
WWOORRLLDD JJOOUURRNNAALL OOFF PPHHAARRMMAACCYY AANNDD PPHHAARRMMAACCEEUUTTIICCAALL SSCCIIEENNCCEESS
VVoolluummee 33,, IIssssuuee 22,, 884444--885577.. RReesseeaarrcchh AArrttiiccllee IISSSSNN 2278 – 4357
Article Received on 02 November 2013, Revised on 03 December 2013, Accepted on 05 January 2014
*Correspondence for
Author:
Prof. Dr. Gehad G. Mohamed
Prof. of Inorganic and ,
Analytical Chemistry,
Associate Editor of J.
Advanced Research (Cairo
University), Chemistry
Department, faculty of Science,
Cairo University, Giza, Egypt.
www.wjpps.com Vol 3, Issue 2, 2014.
845
Gehad et al. World Journal of Pharmacy and Pharmaceutical Sciences
1. INTRODUCTION
The quinolone drugs have been used extensively for the treatment of a broad range of
infections, including urinary tract infections (1) of a wide variety of types, as well as bacterial
infections of the gastrointestinal tract. In addition they are effective for the treatment of
certain type of sexually transmitted diseases (2) and for selected infections of respiratory tract (3), and skin and soft tissues (4). Because of their ability to penetrate into prostatic tissue,
rotatic fluid and their wide spectral activity, these antimicrobial agents are ideal in the
treatment of bacterial prostatitis. Several methods have been reported for the determination of
quinolone in pharmaceutical dosage forms and in biological fluids including HPLC (5-8),
electrochemical (9-12), spectrofluorimetry (13-15), and UV-visible spectrophotometry (16-20).
This paper describes simple, direct, sensitive and precise spectrophotometric methods for the
determination of some quinolone drugs via complexation with some π-acceptors namely
TCNQ and DDQ reagents and with Mo(V)-thiocyanate in acidic medium. Stoichiometry and
molar absorptivity of the formed charge transfer and ion-pair complexes were determined.
Subsequent utilization of these complexes for developing new spectrophotometric methods
for determination of quinolones in pure and pharmaceutical preparations will be discussed in
detailed manner.
2. EXPERIMENTAL
2.1. Reagents
All reagents and chemicals used were of analytical grade and all solutions were freshly
prepared daily. 0.01% (w/v) 7,7,8,8-Tetracyanoquinodimethane (TCNQ), and 5,6-dicyano-
1,4-benzoquinone (DDQ) were prepared in acetonitrile while 0.02% (w/v) Mo(VI) ion was
prepared in bidistilled water. 10% (w/v) of ascorbic acid and ammonium thiocyanate
solutions were prepared. 4M solutions of sulphuric, hydrochloric and nitric acids (Merck)
were prepared by accurate dilution from stock solutions. All solvents used throughout this
study were of analytical grade including acetonitrile (Aldrich), 1,4-dioxane, DMF, ethanol,
methanol, acetone, methylene chloride and 1,2-dichloroethane (El-Nasr company, Egypt).
2.2. Materials
Standard solutions of quinolone drugs under investigation (2.5 x 10-3, 2.8 x 10-3, 2.8 x 10-3
and 2.8 x 10-3 mol L-1 of SFX, LFX, OFX and EFX solutions, respectively) were prepared by
dissolving the accurate weighed amount from each drug in a definite volume of methanol to
get the required concentration. Tablets containing sparfloxacin (200 mg) produced by Jedco
www.wjpps.com Vol 3, Issue 2, 2014.
846
Gehad et al. World Journal of Pharmacy and Pharmaceutical Sciences
Int. Pharm. Co., levofloxacin (500 mg) was supplied from HI PHARM, ofloxacin (200 mg)
was supplied from Sedico Pharm. Co. and enrofloxacin (100 mg) was supplied from
Agricultural Materials Co. Ten tablets were weighed and ground to finally divided powder.
An accurate weight of the powder containing 100 mg of drugs was dissolved in 100 ml
methanol and the solution was filtered off and analyzed using the proposed methods.
2.3. Apparatus
The spectrophotometric measurements were carried out using the manual spectronic 601
(Milton Roy Company) in the wavelength range from 200-800 nm and 1 cm quartz cell was
used.
2.4. Stoichiometry of the formed CT complexes
Stoichiometry of the formed charge transfer complexes was determined by applying the
continuous variation and molar ratio methods (21, 22). Successive aliquots of SFX, LFX and
OFX solutions (5.0 x 10-3 M) in case of DDQ and SFX, LFX and EFX in case TCNQ, so that
the total number of moles was kept constant. The absorbance of the resultant CT complexes
was measured at 460 and 842 nm for DDQ and TCNQ reagents, respectively, against reagent
blank. While in case ion-pair formation, successive aliquots of drug solutions (1.62 x 10-4 M)
with Mo(VI) ion were mixed, and the absorbance was measured at 470 nm.
2.5. General procedure
2.5.1. Batch measurements
Aliquots containing 1 ml of the drugs under investigation (1 mg mL-1) were transferred into
10.0 ml volumetric flask and the same volume of DDQ and TCNQ reagents were added and
the resulting solutions were completed to the mark with acetonitrile. The complete colour
development was attained after 15 and 20 minutes for DDQ and TCNQ reagents,
respectively. The absorbance of the formed complexes was measured at 460 and 842 nm for
DDQ and TCNQ reagents, respectively, against the blank solution prepared without the
drugs. While in case ion-pair formation, the ion-pairs were extracted in 1,2-dichloroethane,
the absorbance was measured after 20, 15, 15 or 15 minutes for SFX, LFX, OFX and EFX
drugs, respectively. The absorbance of the formed ion-pairs complexes were measured at 470
nm.
www.wjpps.com Vol 3, Issue 2, 2014.
847
Gehad et al. World Journal of Pharmacy and Pharmaceutical Sciences
3. RESULTS AND DISCUSSION
3.1. Spectral characteristics
SFX, LFX and EFX drugs, being n-electron donors, reacts with π-acceptors giving
characteristic colour reaction products due to the formation of charge transfer complexes. The
drugs under investigation show negligible absorption in the wavelength range from 400–800
nm in acetonitrile solvent, while addition of the different π-acceptors (namely, DDQ and
TCNQ) to the drug solutions causes change in the absorption spectra due to the formation of
charge transfer complexes with new characteristic bands at maximum absorption depending
on the type of the π-acceptor (Figures 1 and 2). Interaction of SFX, LFX and EFX drugs with
TCNQ gives a green chromogen, which exhibits strong absorption maxima at 842 and 745
nm. The wavelength 842 nm is selected as it gives reproducible results and higher molar
absorptivity. These bands may be attributed to the formation of the radical anion TCNQ•− (22), which is probably formed by the dissociation of an original donor–acceptor (D–A)
complex which is promoted by the high ionizing power of the acetonitrile solvent.
D + A D - A polar solvent
D + A*+ * -**
DA complex Radical ions
* *
Scheme 1.
The interaction of SFX, LFX and OFX drugs with DDQ in acetonitrile at room temperature
give red coloured chromogen with a strong absorption maximum at 460, 565 and 586 nm
where the wavelength 460 is selected for the further studies (23, 24). Interactions of SFX, LFX,
OFX and EFX drugs with Mo(V)-thiocyanate in sulphuric acid medium give an extractable
ion-pairs orange product in 1,2-dichloroethane with absorption maximum at 470 nm.
3.2. Optimization of reaction conditions
3.2.1. Effect of reagent concentration.
To establish the optimum experimental conditions for SFX, LFX, OFX and EFX charge
transfer complexes, the drugs (100 µg mL–1) are allowed to react with varying volumes of
the different acceptors (DDQ and TCNQ). It is found that maximum absorbance is obtained
after the addition of 200 µg mL-1 of DDQ and TCNQ reagents and higher concentrations of
these reagents have no effect that may be useful for rapidly reaching equilibrium, thus
minimizing the time required for attaining maximum absorbance at the corresponding
wavelengths. While in case of ion-pair formation, 50, 30, 30 and 30 µg mL–1 of SFX, LFX,
OFX and EFX drugs are allowed to react with varying volumes of Mo(VI) ion (0.02%
www.wjpps.com Vol 3, Issue 2, 2014.
848
Gehad et al. World Journal of Pharmacy and Pharmaceutical Sciences
(w/v)). The results obtained show that 250, 250, 200 and 200 µg mL-1 of Mo(VI) are suitable
for determination of SFX, LFX, OFX and EFX drugs in pure form and tablets.
3.2.2. Effect of solvents
In order to select the suitable solvent for charge transfer complex formation, the reaction of
the drugs under investigation with DDQ and TCNQ reagents is made in different solvents.
Acetonitrile shows super priority over chloroform, 2-propanol, 1,2-dichloroethane, 1,4-
dioxane, methanol and ethanol as the complex formed in these solvents either have low
absorbance or precipitated on dilution. Further, acetonitrile, being a polar solvent, facilitates
the complete transfer of charge from donor to acceptor with the formation of radical anion as
the predominant chromogen indicated by high ε values, which is attributed to its high
dielectric constant (25). While in case of ion-pair formation, the reaction of the drugs under
investigation with Mo(VI) ion is made in different solvents. 1,2-Dichloroethane was selected
as the suitable solvent for the extraction as it provides the highest molar absorptivity value.
3.2.3. Effect of reaction time
It is obvious from Figures (3 and 4) that complete colour development is attained
immediately at room temperature after 15 and 20 min using DDQ and TCNQ reagents,
respectively. In addition the extracted ion-pairs of the orange quinolone drugs under
investigation and Mo(VI)-thiocyanate attain maximum absorbance after 15-20 min (Figure
5). The absorbance of the charge transfer complexes or ion-pairs remain stable for at least one
day.
3.2.4. Effect of reaction temperature
The effect of temperature of the formed charge transfer complexes is determined in the range
0-50 °C using DDQ and TCNQ and Mo(V)-thiocyanate reagents, respectively, with SFX,
LFX or OFX and SFX, LFX or EFX drugs, respectively. From the results, the absorbance
attains maximum value at 25-30 °C for DDQ and TCNQ reagents, respectively. In addition,
the extracted ion-pairs of the orange quinolone drugs under investigation and Mo(V)-
thiocyanate attain maximum absorbance at 30 °C.
3.2.5. Stoichiometry of the formed charge transfer and ion-pair complexes [21, 22]
The stoichiometric ratio between the drugs under investigation and the reagents is determined
by applying the molar ratio and continuous variation methods. The results obtained reveal
that 1:1 [Drug]: [Reagents] are formed. This finding is anticipated by the presence of basic
www.wjpps.com Vol 3, Issue 2, 2014.
849
Gehad et al. World Journal of Pharmacy and Pharmaceutical Sciences
electron-donating center (nitrogen atom) in the drugs under investigation. The results indicate
that ions pairs are formed through the electrostatic attraction between positive protonated
drugs and thiocyanate negative complex.
3.3. Validity of Beer's Law
Under the optimum conditions described above, the calibration graphs are constructed for the
investigated drugs applying the two different acceptors. The molar absorptivities, standard
deviations, concentration ranges, limits of detection and quantification for each reagent are
tabulated in Tables (1, 2). Beer’s law is valid over the concentration range from 5-150 µg ml-1
of SFX, LFX and OFX drugs using DDQ reagent and 5-180 µg ml-1 of of SFX, LFX and EFX
drugs using TCNQ reagent. While the calibration curves are linear in the concentration range
from 10-150, 10-125, 10-90 and 10-90 µg ml-1 of SFX, LFX, OFX and EFX drugs using
Mo(V)-thiocyanate reagent.
The high correlation coefficients and low values of the relative standard deviations indicate
the high accuracy and precision of the method.
3.4. Between-day determination of SFX, LFX, OFX and EFX
In order to prove the validity and applicability of the proposed method and reproducibility of
the results obtained, four replicate experiments at four concentrations of the quinolone drugs
under investigation are carried out. Table (3) show the values of the between-day relative
standard deviations for different concentrations of the drugs, obtained from experiments
carried out over a period of four days. It is found that, the between day relative standard
deviations are less than 1%, which indicates that the proposed method is highly reproducible
and DDQ, TCNQ and Mo(VI) reagents are successfully applied to determine SFX, LFX,
OFX and EFX drugs via the charge transfer reaction and ion-pair formation.
3.5. Spectrophotometric determination of quinolone drugs in Pharmaceutical
Preparations
The spectrophotometric microdetermination of SFX, LFX, OFX and EFX drugs via their
reactions with DDQ, TCNQ (strong electron acceptors) and Mo(VI) thiocyanate reagents are
carried out. The results obtained are given in Table (4). These data show that, the determined
concentrations of the quinolone drugs by the proposed methods are closed to that calculated
from the applied standard methods (26-29). In order to check the confidence and correlation
between the suggested spectrophotometric procedures and the official method for
www.wjpps.com Vol 3, Issue 2, 2014.
850
Gehad et al. World Journal of Pharmacy and Pharmaceutical Sciences
microdetermination of these drugs, the percent recovery for all the results are calculated. The
percentage recovery values obtained by the proposed methods are higher than or close to
those obtained by the official method. In addition, the standard deviation values obtained by
the proposed methods are lower than those obtained by the official method. The small values
of standard deviation and relative standard deviation indicate the reliability, accuracy and
precision of the suggested procedures.
Table (1). The analytical parameters for the determination of SFX, LFX OFX and EFX
drugs using DDQ, TCNQ and Mo(V) reagents.
Drug Reagent SFX LFX OFX EFX
λmax (nm) DDQ
TCNQ Mo(V)
460 842 470
460 842 470
460 ----- 470
----- 842 470
[Drug], g ml-1 DDQ
TCNQ Mo(V)
5-150 5-180 10-150
5-150 5-180
10-125
5-150 ----
10-90
----- 5-180 10-90
ε ( L.mol-1.cm-1) DDQ
TCNQ Mo(V)
38x105 46x105 62x105
18x105 34x105 144x105
26x105 -----
89x105
----- 36x105 93x105
Sandel sensitivity; ng cm-2
DDQ TCNQ Mo(V)
1.7 1.8
1.18
1.15 1.14
1.143
1.2 ------ 1.33
------ 1.16 1.14
A = mC+Z
m DDQ
TCNQ Mo(V)
0.0042 0.0035 0.0035
0.005 0.0059 0.0035
0.0069 -----
0.0062
------ 0.0055 0.0060
Z DDQ
TCNQ Mo(V)
0.1598 0.2192 0.1286
0.1756 0.1367 0.1006
0.1875 ------
0.0511
---- 0.0901 0.1235
Correlation coefficient (r2)
DDQ TCNQ Mo(V)
0.9944 0.9987 0.9963
0.9974 0.9991 0.9965
0.9971 ------
0.9977
------- 0.9995 0.9938
SD* DDQ
TCNQ Mo(V)
0.013-0.060 0.015-0.061 0.013-0.062
0.018-0.061 0.015-0.054 0.023-0.060
0.018-0.053 -- ----
0.015-0.044
------ 0.012-0.060 0.022-0.080
RSD* % DDQ
TCNQ Mo(V)
0.011-0.500 0.01-0.096 0.01-0.15
0.013-0.84 0.01-0.62 0.03-0.26
0.012-0.760 -------
0.02-0.20
------ 0.01-0.86 0.03-0.41
LOD; g mL-1 DDQ
TCNQ Mo(V)
4.00 3.90 9.00
3.80 8.00 6.00
6.00 ----- 6.80
----- 7.80 7.60
LOQ; g mL-1 DDQ
TCNQ Mo(V)
2.80 2.60 3.40
2.00 4.50 4.70
3.50 ------ 5.00
---- 6.00 6.50
* Number of replicates (n) = 5.
www.wjpps.com Vol 3, Issue 2, 2014.
851
Gehad et al. World Journal of Pharmacy and Pharmaceutical Sciences
Table (2). The absorbance and molar absorptivity () values for the determination of
SFX, LFX, OFX and EFX drugs using Mo(V)-thiocyanat in different solvents.
(L.mol-1 cm-1 ) A Solvent
EFX OFX LFX SFX EFX OFX LFX SFX
------ ------ ------ ------ ------ ------
44x105 30x105 40x105 3x105
25x105 13x105
24x105 23x105 18x105 11x105 16x105 17x105
56x105 40x105 47x105 2x105
51x105 33x105
------ ------ ------ ------ ------ ------
1.23 0.82 1.11 0.08 0.68 0.36
0.65 0.64 0.51 0.30 0.45 0.48
1.43 1.01 1.21 0.01 1.30 0.34
Using DDQ Acetonitrile Methanol Dimethylformamide 1,4-Dioxane Chloroform Benzene
48x105 30x105 46x105 27x105 26x105 43x105
------ ------ ------ ------ ------ ------
47x105 30x105 44x105 19x105 31x105 36x105
56x105 29x105 55x105 38x105 47x105 51x105
1.33 0.82 1.29 0.75 0.71 1.19
------ ------ ------ ------ ------ ------
1.29 0.84 1.21 0.53 0.86 0.99
1.44 0.75 1.40 0.97 1.19 1.31
Using TCNQ Acetonitrile Methanol Dimethylformamide Isobutyl alcohol n-Butanol Ethanol
93 x 105 50 x 105
89 x 105 40 x 105
144 x 105 48 x 105
62 x 105 27 x 105
0.78 0.42
0.74 0.40
1.2 0.33
0.80 0.34
Using Mo(V) thiocyanate 1,2-Dichloroethane Methylene chloride
Table (3). Between- day precision of the microdetermination of SFX, LFX, OFX and
EFX drugs by the proposed method.
Drug
[Drug] Taken g mL-1
[Drug] Found g mL-1
(%) Recovery
SD RSD (%)
DDQ reagent 20.00 40.00 100.0
19.98 40.05 100.0
99.90 100.1 100.0
0.017 0.015 0.012
0.085 0.037 0.012
SFX
LFX
20.00 100.0 130.0
20.10 100.2 129.5
100.5 100.2 99.62
0.140 0.132 0.132
0.690 0.132 0.101
OFX
40.00 60.00 120.0
40.40 60.30 119.8
101.0 100.5 99.83
0.193 0.173 0.055
0.480 0.290 0.046
TCNQ reagent SFX
40.00 60.00 100.0
40.01 59.99 99.96
100.0 99.98 99.96
0.016 0.034 0.014
0.040 0.057 0.014
LFX
40.00 60.00 100.0
40.03 59.99 99.99
100.0 99.98 99.99
0.012 0.005 0.012
0.030 0.008 0.012
www.wjpps.com Vol 3, Issue 2, 2014.
852
Gehad et al. World Journal of Pharmacy and Pharmaceutical Sciences
Table (4). Spectrophotometric determination of
SFX, LFX, OFX and EFX drugs in pharmaceutical preparations
Name of drug preparation
[Drug] g mL-1
% Found ± SD(n = 5) Official method
Proposed methods TCNQ DDQ Mo(V)
Parox 200 mg
80.00 100.0
99.6±0.1 99.5±0.5 t = 0.452 F = 3.14
99.6±0.1 99.5±0.5 t = 0.452 F = 3.15
99.9±0.03 99.7±0.07 t = 0.452 F = 3.15
99.4±0.05
UniBiotic 500 mg
80.00 100.0
99.9±0.01 99.8±0.04 t = 0.452 F = 3.15
99.6±0.1 99.5±0.5 t = 0.452 F = 3.15
99.6±0.1 99.5±0.5 t = 0.452 F = 3.15
99.9±0.34
Ofloxacin 200 mg
80.00 100.0
----------
-----------
99.6±0.1 99.5±0.5 t = 0.452 F = 3.15
99.6±0.1 99.5±0.5 t = 0.452 F = 3.15
99.4±0.81
Enrovet solution 100 mg
80.00 100.0
99.9±0.1 100.1±0.5 t = 0.521 F = 4.15
--------------- --
----------------
99.9±0.1 100.1±0.5 t = 0.352 F = 4.15
99.6±0.06
Tabulated t-test value at 95% confidence level = 2.77.
Tabulated F-test value at 95% confidence level = 6.39.
EFX
40.00 60.00 100.0
39.99 59.97 100.0
99.97 99.95 100.0
0.010 0.019 0.012
0.025 0.031 0.012
Mo(V)-thiocyanate reagent SFX
20.00 50.00 100.0
19.90 50.15 99.80
99.50 100.3 99.80
0.28 0.60 0.06
0.06 0.30 0.06
LFX
75.00 100.0 125.0
75.04 99.90 125.3
103.0 99.90 101.2
0.37 0.65 0.20
0.29 0.65 0.25
OFX
30.00 50.00 90.00
29.97 50.00 90.00
99.90 100.0 100.0
0.09 0.08 0.01
0.03 0.04 0.01
EFX
50.00 90.00 100.0
50.04 90.00 99.98
100.1 100.0 99.98
0.05 0.02 0.08
0.02 0.02 0.08
www.wjpps.com Vol 3, Issue 2, 2014.
853
Gehad et al. World Journal of Pharmacy and Pharmaceutical Sciences
00.10.20.30.40.50.60.70.8
400 500 600 700
Wavelength (nm)
Abs
orba
nce
Figure (1). Absorption spectra of (a) DDQ in acetonitrile and ( b) SFX–, (c) LFX– and
(d) OFX–DDQ CT complexes in acetonitrile.
0
0.2
0.4
0.6
0.8
1
1.2
600 650 700 750 800 850 900 950
Wavelength (nm)
Abs
orba
nce
Figure (2). Absorption spectra of (a) TCNQ in acetonitrile and (b) SFX–, (c) LFX– and
(d) EFX–DDQ CT complexes in acetonitrile.
(a)
0.30.40.50.60.70.80.9
0 50 100
Abs
orba
nce
Time (min)
a
b
d d c
a
b c d
www.wjpps.com Vol 3, Issue 2, 2014.
854
Gehad et al. World Journal of Pharmacy and Pharmaceutical Sciences
(b)
0.3
0.4
0.5
0.6
0.7
0 20 40 60 80
Time (min)
Abs
orba
nce
SFXLFXEFX
(c)
Fig. (3) : Effect of time on the spectra of
(a) CT complexes of SFX, LFX and OFX drugs with DDQ in acetonitrile, max = 460 nm. (b) CT complexes of SFX, LFX and EFX drugs with TCNQ in acetonitrile, max = 842 nm. (c) Ion-pairs of SFX, LFX, OFX and EFX drugs in dichloroethane at max = 470 nm.
(a)
0.4
0.5
0.6
0.7
0.8
0.9
0 10 20 30 40 50 60 70
Time (min)
Abs
orba
nce SFX
LFXOFXEFX
0
0 .5
1
1 .5
2
2 .5
0 1 2 3
Absorbance
[DDQ] / [Drug]
SFX
LFX
OFX
www.wjpps.com Vol 3, Issue 2, 2014.
855
Gehad et al. World Journal of Pharmacy and Pharmaceutical Sciences
(b)
(c)
Figure (4). Stiochiomertric ratio of the reaction of
(a) CT complexes of SFX, LFX and OFX drugs with DDQ in acetonitrile, max = 460 nm.
(b) CT complexes of SFX, LFX and EFX drugs with TCNQ in acetonitrile, max = 842 nm.
(c) Mo(V)-thiocyanate with OFX and EFX drugs in dichloroethane at max = 470 nm.
4. CONCLUSION
This paper demonstrated that charge transfer complexes and ion-pair formations can be
utilized as useful reagents for the spectrophotometric determination of quinolone drugs under
investigation. Rapid formation of stable charge transfer complexes and ion-pair formations
and no need for extraction or separation processes are advantages of the suggested method
over the previously reported spectrophotometric methods. The proposed spectrophotometric
methods are simpler, time saving, and they involve very simple procedures, that can be
applied in routine analysis.
0
0.5
1
1.5
2
0 1 2 3
[TCNQ] / [Drug]
Abs
orba
nce
SFXLFXEFX
0
0.5
1
1.5
2
0 1 2 3
[TCNQ] / [Drug]
Abs
orba
nce
SFXLFXEFX
www.wjpps.com Vol 3, Issue 2, 2014.
856
Gehad et al. World Journal of Pharmacy and Pharmaceutical Sciences
REFERENCES
1- Norrby,S.R.M., Treatment of Urinary Tract Infections with Quinolone, Antimicrobial
agent, in Quinolone Antimicrobial agents, Wolfson, J.S. and Hooper, D.C. (Eds)
American society for Microbiology, Washington, D.C. 20006 (1989).
2- Dallabetta, G.A. and Hook III, E.W., Treatment of Sexually Transmitted Diseases with
Quinolon Antimicrobial agents, Wolfson, J.S. and Hooper, D.C. (Eds) A.S. for
Microbiology, Washington, D.C. (1989).
3- Scully,B.E., Treatment of Respiratory Tract Infections with Quinolon Antimicrobial
agents, in Quinolone Antimicrobial agents, Wolfson, J.S. and Hooper, D.C. (Eds)
American Society for Microbiology, Washington, D.C. (1985).
4- Hooper, D.C.; Wolfson, J.S., Treatment of skin and soft Tissue Infections with Quinolon
Antimicrobial agents, Wolfson, J.S. and Hooper, D.C. (Eds) American Society for
Microbiology, Washington, D.C. (1989).
5- Sun, Y.A.; Wang, G.Q.; Cui, Q.Z., Fenxi.Ceshi.Xuebao, 19(1), 62-64, (2006).
6- Nguyen, H.A.; Grellet, J.; Ba, B.B.; Quentin, C.; Saux, M.C., J. Chromatogr. B., 810(1),
77-83, (2004).
7- Espinosa-Mansilla, A.; Munoz-de-la-pena, A.; Gonzolez-Gomez, D.; Salinase-Lopez, F.,
Talanta, 68(4), 1215-1221, (2006).
8- Idowu, O. R.; Peggins, J.O., J. Pharm. Biomed. Anal., 35(1), 143-153, (2004).
9- Huang, C.L.; Liu, J.; Li, R.F.; Xiu, R., Fenxi. Shiyanshi, 25(1), 95-98, (2006).
10- Radi, A.; El-Ries, M.A.; Kandil, S., Anal. Chem. Acta, 495(1-2), 61-67, (2003).
11- Qian, Y.G.; Shang, J.; Li, Q.L.;Lu, Y.Q., Fenxi. Shiyanshi, 20(2), 83-86, (2001).
12- Qzkan, S.A.; Uslu, B.; Aboul-Enein, H.Y., Crit. Rev. Anal. Chem, 33(3), 155-181,
(2003).
13- Du, L.M.; Fan, Z.F.; Guo, Q.E., Fenxi. Huaxue, 29(3), 249-252, (2001).
14- Du, L.M.; Yang, Y.Q.; Wang, Q.M., Anal. Chem. Acta, 516(1), 237-243, (2004).
15- Espinosa-Mansilla, A.; de-la-pena, A.M.; Canada-Canada, F.; Gonzalez-Gomez, D.,
Anal. Biochem, 347(2), 725-286 (2005).
16- Wen, J.W.; Zheng, Z.D., Yaowu. Fenxi. Zazhi, 20(4), 269, (2000).
17- Hu, C.Q.; Jiang, J.; Gu, D.Z., Yaowu. Fenxi. Zazhi, 19(6), 371-375, (1999)
18- Sulsu, I.; Tamer, A., Anal. Lett, 36(6), 1163-1181, (2003).
19- Mostafa, S.; El-Sadek, M.; Alla, E.A.; J.Pharm.Biomed. Anal, 28(1), 173-180, (2002).
20- Jop, P., Ann. Chim., 9, 113, (1928).
21- Vosburgh, W.C.; Cooper, G.R., J. Am. Chem. Soc., 63, 437, (1941).
www.wjpps.com Vol 3, Issue 2, 2014.
857
Gehad et al. World Journal of Pharmacy and Pharmaceutical Sciences
22- F.A. Nour El-Dien, Gehad G. Mohamed, Eman Y. Frag. Chemical Papers, 63(6), 646-
653, 2009.
23-Abdel-Hamid, M.E.; Abdel-Salam, M.A.; Mahrous, M.S.; Abdel-Khalek, M.M. Talanta,
2(10), 1002, (1985).
24- Abdel-Salam, M.A.; Issa, A.S.; Mahrous, M.S.; Abdel-Hamid, M.E., Anal. Lett. 18(B
11), 1319, (1985).
25- Vogel’s Textbook of Practical Organic Chemistry, 5th ed., Longman Group UK Ltd.,
England, 1989, pp. 1442–1444.
26- Chaudhuri, J.J.; Sharma, A.V.; Tharkorke, K.H.; Tarivedi, J.K., Indian drugs, 36(7), 474-
475, (1999).
27- Clark's Analysis of Drugs and Poisons 3rd Edition, Pharmaceutical Press London, 1172,
(2004).
28- TheUnited States Pharmacopeia, (USP 25), 1262-1263, (2002).
29- Zeinab, A. ELsherif., Analytical Letters, 32(1), 65-78, (1999).